Valuation check: ACRX's profit margin is -14253.0%, below the Healthcare sector average of 15.58%.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2026
Trailing 12 months ending Mar 2026
Acelrx Pharmaceuticals posts a profit margin of -14253.0% as of March 2026. That compares with 65.27% in the prior-year period — down 21938.6% year over year. That is below the Healthcare sector average of 15.58%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
In the prior comparable period, Acelrx Pharmaceuticals's profit margin was 65.27%. The latest reading is -14253.0% — a 21938.6% year-over-year decrease (period ending March 2026). Use the history and growth charts on this page for a longer lookback.
For Healthcare stocks, a profit margin near 15.58% is typical. Acelrx Pharmaceuticals's -14253.0% is lower that level. That is roughly 9146000.6% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Acelrx Pharmaceuticals's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -14253.0% as of March 2026; use YoY and peer views to separate noise from signal.
Context for ACRX's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 15.58%), and (3) consistency with growth and profitability. This page covers the first two; Acelrx Pharmaceuticals's other metric pages and overview cover the third.